Using patient-derived T cells to target pancreatic cancer after chemotherapy
A Phase 1 Study of Patient-Derived Multi-Tumor Associated Antigen Specific T Cells (MT-601) Administered to Patients with Metastatic Pancreatic Cancer following frontline FOLFIRINOX
['FUNDING_SBIR_2'] · MARKER THERAPEUTICS, INC. · NIH-11006021
This study is testing a new treatment called MT-601, which uses specially modified T cells from your own blood to help fight metastatic pancreatic cancer after you've had FOLFIRINOX chemotherapy, with the hope of improving how well your body can target and control the cancer.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MARKER THERAPEUTICS, INC. (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-11006021 on ClinicalTrials.gov |
What this research studies
This research investigates a novel T cell therapy called MT-601, which is designed to target multiple tumor-associated antigens in patients with metastatic pancreatic cancer who have undergone initial treatment with FOLFIRINOX chemotherapy. The therapy utilizes T cells derived from the patient's own blood, which are then modified to enhance their ability to recognize and attack cancer cells. By focusing on the tumor microenvironment, the goal is to improve T cell infiltration and activation, ultimately leading to better control of tumor growth. Patients will be monitored for safety and effectiveness as the treatment progresses.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic pancreatic cancer who have received frontline FOLFIRINOX chemotherapy.
Not a fit: Patients with early-stage pancreatic cancer or those who have not undergone FOLFIRINOX chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, more effective treatment option for patients with metastatic pancreatic cancer, potentially extending survival beyond current standards.
How similar studies have performed: While immunotherapy has shown promise in hematologic cancers, its application in pancreatic cancer is still emerging, making this approach relatively novel.
Where this research is happening
HOUSTON, UNITED STATES
- MARKER THERAPEUTICS, INC. — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: VERA, JUAN FERNANDO — MARKER THERAPEUTICS, INC.
- Study coordinator: VERA, JUAN FERNANDO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.